STOCK TITAN

Roivant Sciences (NASDAQ: ROIV) holder files to sell 200,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Roivant Sciences Ltd. has a shareholder planning to sell 200,000 common shares through Rockefeller Financial LLC on NASDAQ, with an indicated aggregate market value of $4,383,694.07 and 695,491,615 common shares outstanding. The shares are tied to an option exercise dated 01/12/2026, from an award granted on 04/20/2022, with payment made by wire.

Recent trading history shows the same account has sold multiple Roivant common share blocks over the past three months, including 414,683 shares on 10/15/2025 for gross proceeds of $7,021,429.14 and 200,000 shares on 12/23/2025 for $4,490,540.00. The seller represents that they do not know of any material adverse, nonpublic information about Roivant’s current or prospective operations.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Roivant Sciences

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Latest SEC Filings

ROIV Stock Data

16.20B
455.99M
26.13%
76.8%
5.72%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON